These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 30108375)

  • 21. Magnetic Resonance Imaging Targeted Biopsy Improves Selection of Patients Considered for Active Surveillance for Clinically Low Risk Prostate Cancer Based on Systematic Biopsies.
    Ouzzane A; Renard-Penna R; Marliere F; Mozer P; Olivier J; Barkatz J; Puech P; Villers A
    J Urol; 2015 Aug; 194(2):350-6. PubMed ID: 25747105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Increase in Gleason 6 Tumor Volume While on Active Surveillance Portends a Greater Risk of Grade Reclassification with Further Followup.
    Komisarenko M; Wong LM; Richard PO; Timilshina N; Toi A; Evans A; Zlotta A; Kulkarni G; Hamilton R; Fleshner N; Finelli A
    J Urol; 2016 Feb; 195(2):307-12. PubMed ID: 26417646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
    Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
    Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective validation of microseminoprotein-β added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort.
    Lonergan PE; Vertosick EA; Assel M; Sjoberg DD; Haese A; Graefen M; Boorjian SA; Klee GG; Cooperberg MR; Pettersson K; Routila E; Vickers AJ; Lilja H
    BJU Int; 2021 Aug; 128(2):218-224. PubMed ID: 33306251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance.
    Ferro M; Lucarelli G; Bruzzese D; Di Lorenzo G; Perdonà S; Autorino R; Cantiello F; La Rocca R; Busetto GM; Cimmino A; Buonerba C; Battaglia M; Damiano R; De Cobelli O; Mirone V; Terracciano D
    Oncotarget; 2017 Mar; 8(11):18424-18434. PubMed ID: 27793023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High risk of under-grading and -staging in prostate cancer patients eligible for active surveillance.
    Heidegger I; Skradski V; Steiner E; Klocker H; Pichler R; Pircher A; Horninger W; Bektic J
    PLoS One; 2015; 10(2):e0115537. PubMed ID: 25658878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer.
    Punnen S; Pavan N; Parekh DJ
    Rev Urol; 2015; 17(1):3-13. PubMed ID: 26028995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of high-grade prostate cancer risk using prostate cancer biomarkers.
    Stanton WN; Crawford ED; Arangua PB; La Rosa FG; van Bokhoven A; Lucia MS; Poage WL; Partin A; Maroni P; Werahera PN
    Can J Urol; 2020 Feb; 27(1):10080-10085. PubMed ID: 32065862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multi-parametric magnetic resonance imaging monitoring patients in active surveillance for prostate cancer: a prospective cohort study.
    Elkjær MC; Andersen MH; Høyer S; Pedersen BG; Borre M
    Scand J Urol; 2018 Feb; 52(1):8-13. PubMed ID: 29212392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly.
    Bhindi B; Kulkarni GS; Finelli A; Alibhai SM; Hamilton RJ; Toi A; van der Kwast TH; Evans A; Hersey K; Jewett MA; Zlotta AR; Trachtenberg J; Fleshner NE
    Eur Urol; 2014 Nov; 66(5):841-8. PubMed ID: 24954793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The 4Kscore blood test accurately identifies men with aggressive prostate cancer prior to prostate biopsy with or without DRE information.
    Zappala SM; Dong Y; Linder V; Reeve M; Sjoberg DD; Mathur V; Roberts R; Okrongly D; Newmark J; Sant G; Steiner M
    Int J Clin Pract; 2017 Jun; 71(6):. PubMed ID: 28497893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study.
    Bul M; Zhu X; Valdagni R; Pickles T; Kakehi Y; Rannikko A; Bjartell A; van der Schoot DK; Cornel EB; Conti GN; Boevé ER; Staerman F; Vis-Maters JJ; Vergunst H; Jaspars JJ; Strölin P; van Muilekom E; Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2013 Apr; 63(4):597-603. PubMed ID: 23159452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 4Kscore Cut-off of 7.5% for Prostate Biopsy Decisions Provides High Sensitivity and Negative Predictive Value for Significant Prostate Cancer.
    Bhattu AS; Zappala SM; Parekh DJ; Punnen S
    Urology; 2021 Feb; 148():53-58. PubMed ID: 33217456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic significance of perineural invasion and race in men considering active surveillance.
    Cohn JA; Dangle PP; Wang CE; Brendler CB; Novakovic KR; McGuire MS; Helfand BT
    BJU Int; 2014 Jul; 114(1):75-80. PubMed ID: 24106869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men.
    Punnen S; Freedland SJ; Polascik TJ; Loeb S; Risk MC; Savage S; Mathur SC; Uchio E; Dong Y; Silberstein JL
    J Urol; 2018 Jun; 199(6):1459-1463. PubMed ID: 29223389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
    Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
    J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of predictors of unfavorable pathological features in men eligible for active surveillance using radical prostatectomy specimens: a multi-institutional study.
    Mizuno K; Inoue T; Kinoshita H; Yano T; Kawanishi H; Kanda H; Terada N; Kobayashi T; Kamba T; Mikami Y; Shiraishi T; Uemura Y; Imai Y; Honjo G; Shirase T; Okumura K; Kawakita M; Ogura K; Sugimura Y; Matsuda T; Ogawa O
    Jpn J Clin Oncol; 2016 Dec; 46(12):1156-1161. PubMed ID: 27744325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression.
    Wong LM; Alibhai SM; Trottier G; Timilshina N; Van der Kwast T; Zlotta A; Lawrentschuk N; Kulkarni G; Hamilton R; Ferrara S; Margel D; Trachtenberg J; Jewett MA; Toi A; Evans A; Fleshner NE; Finelli A
    Eur Urol; 2014 Sep; 66(3):406-13. PubMed ID: 23664820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.